Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus–positive kidney transplant recipient. Issue 4 (20th June 2016)

• Record Type: Journal Article
• Authors: Lee, D.H.; Malat, G.E.; Bias, T.E.; Harhay, M.N.; Ranganna, K.; Doyle, A.M.
• Is Part Of: Transplant infectious disease. Volume 18:Issue 4(2016)
• Page Start: 625
• Page End: 627
• Publication Date: 2016-06-20
• Subjects: dolutegravir -- kidney transplant -- creatinine -- human immunodeficiency virus -- antiretroviral; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12545
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Dolutegravir is a preferred antiretroviral drug for human immunodeficiency virus (HIV)‐infected patients following solid organ transplantation. It has potent antiretroviral activity and does not interact with calcineurin inhibitors. We describe a case of an HIV‐infected kidney transplant patient, who was noted to have a rising serum creatinine following initiation of dolutegravir. At first, an acute rejection episode was suspected, but this finding was later attributed to inhibition of creatinine secretion by dolutegravir. We suggest that an awareness of this potential effect of dolutegravir is important for providers who take care of HIV‐positive kidney transplant recipients, in order to prevent potentially unnecessary testing.